ALZHEIMER'S DRUG DISCOVERY FOUNDATION

aka ADDF   |   NEW YORK, NY   |  www.alzdiscovery.org

Mission

ACCELERATE THE DISCOVERY AND DEVELOPMENT OF DRUGS TO PREVENT, TREAT AND CURE ALZHEIMER'S DISEASE, RELATED DEMENTIAS AND COGNITIVE AGING

Ruling year info

2005

Founding Executive Director and Chief Science Officer

Howard Fillit MD

Main address

57 W. 57th St. Suite 904

NEW YORK, NY 10019 USA

Show more contact info

Formerly known as

Institute for the Study of Aging

EIN

20-1082179

NTEE code info

Alzheimer's (H83)

IRS filing requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Sign in or create an account to view Form(s) 990 for 2019, 2018 and 2017.
Register now

Communication

Programs and results

What we aim to solve

This profile needs more info.

If it is your nonprofit, add a problem overview.

Login and update

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

Drug Discovery

The ADDF is focused on translational research—translating the knowledge we have gained about the underlying causes of Alzheimer's disease into drugs. We fund programs in academia and biotechnology companies worldwide, with priority funding in drug development, clinical trials, biomarkers, and prevention.

Population(s) Served
Seniors

ADDF Access provides academic and small biotechnology researchers with access to a virtual network of contract research organizations, drug development experts and educational resources.

Population(s) Served
Adults

The ADDF's Aging and Alzheimer's Prevention program provides an independent scientific evaluation of the evidence surrounding pharmaceuticals, supplements and natural products that claim to prevent or delay cognitive aging and Alzheimer's. The program also works to enhance innovative approaches to strengthen the evidence for prevention through targeted funding.

Population(s) Served
Adults

Where we work

Our results

SOURCE: Self-reported by organization

How does this organization measure their results? It's a hard question but an important one.

Total dollar amount of grants awarded

This metric is no longer tracked.
Totals By Year
Related Program

Drug Discovery

Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

Total number of grants awarded

This metric is no longer tracked.
Totals By Year
Related Program

Drug Discovery

Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

Number of organizational partners

This metric is no longer tracked.
Totals By Year
Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

Number of organizations applying for grants

This metric is no longer tracked.
Totals By Year
Type of Metric

Input - describing resources we use

Direction of Success

Increasing

Goals & Strategy

SOURCE: Self-reported by organization

Learn about the organization's key goals, strategies, capabilities, and progress.

Charting impact

Four powerful questions that require reflection about what really matters - results.

We aim to support the most promising, novel Alzheimer's drug discovery research--from drug target validation through early-phase clinical trials--to find an effective treatment, and cure, for Alzheimer's disease and related dementias.

We regularly seek and promote requests for proposals from researchers around the world; evaluate the promise of these proposals with our team of neuroscientists and our independent, renowned Scientific Review Board; and invest in the research that our team has deemed the most promising.

We have a highly regarded science team led by Howard Fillit, MD, a leader in geriatric medicine, and a supporting staff of four PhD neuroscientists. Additionally, our Scientific Review Board provides outside, independent evaluation of the quality of the grant proposals we receive and make recommendations for funding.

In 2013, we invested more than $8 million in the drug discovery research recommended by this team.

Though we do not yet have an FDA-approved, disease-modifying treatment for Alzheimer's disease or a related dementia, we have made significant progress. In 2012, the US Food and Drug Administration (FDA) approved Amyvid™, the first diagnostic test for Alzheimer's disease. The ADDF seed-funded the research for Amyvid™ from 2000–2004. Amyvid™ is improving and accelerating clinical trials for by ensuring that all patients enrolled have Alzheimer's disease.

Of the nearly 500 programs in which we've invested, 38 have advanced to the clinical trial stage and more than 20 of those are ongoing. Programs we have funded represent approximately 20% of all treatments currently in clinical trials for Alzheimer's (using October 2015 data from clinicaltrials.gov and Alzforum.org).

Financials

ALZHEIMER'S DRUG DISCOVERY FOUNDATION
lock

Unlock financial insights by subscribing to our monthly plan.

Subscribe

Unlock nonprofit financial insights that will help you make more informed decisions. Try our monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights?
Learn more about GuideStar Pro.

Operations

The people, governance practices, and partners that make the organization tick.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

ALZHEIMER'S DRUG DISCOVERY FOUNDATION

Board of directors
as of 10/7/2021
SOURCE: Self-reported by organization
Board co-chair

Leonard A. Lauder


Board co-chair

Ronald S. Lauder

Board leadership practices

SOURCE: Self-reported by organization

GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section.

  • Board orientation and education
    Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations? No
  • CEO oversight
    Has the board conducted a formal, written assessment of the chief executive within the past year ? Yes
  • Ethics and transparency
    Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year? Yes
  • Board composition
    Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership? Yes
  • Board performance
    Has the board conducted a formal, written self-assessment of its performance within the past three years? No

Organizational demographics

SOURCE: Self-reported; last updated 10/20/2020

Who works and leads organizations that serve our diverse communities? GuideStar partnered on this section with CHANGE Philanthropy and Equity in the Center.

Leadership

No data

Race & ethnicity

Gender identity

 

Sexual orientation

No data

Disability

No data

Equity strategies

Last updated: 10/20/2020

GuideStar partnered with Equity in the Center - an organization that works to shift mindsets, practices, and systems to increase racial equity - to create this section. Learn more

Data
  • We review compensation data across the organization (and by staff levels) to identify disparities by race.
  • We ask team members to identify racial disparities in their programs and / or portfolios.
  • We analyze disaggregated data and root causes of race disparities that impact the organization's programs, portfolios, and the populations served.
  • We disaggregate data to adjust programming goals to keep pace with changing needs of the communities we support.
  • We employ non-traditional ways of gathering feedback on programs and trainings, which may include interviews, roundtables, and external reviews with/by community stakeholders.
  • We disaggregate data by demographics, including race, in every policy and program measured.
  • We have long-term strategic plans and measurable goals for creating a culture such that one’s race identity has no influence on how they fare within the organization.
Policies and processes
  • We use a vetting process to identify vendors and partners that share our commitment to race equity.
  • We have a promotion process that anticipates and mitigates implicit and explicit biases about people of color serving in leadership positions.
  • We seek individuals from various race backgrounds for board and executive director/CEO positions within our organization.
  • We have community representation at the board level, either on the board itself or through a community advisory board.
  • We help senior leadership understand how to be inclusive leaders with learning approaches that emphasize reflection, iteration, and adaptability.
  • We measure and then disaggregate job satisfaction and retention data by race, function, level, and/or team.
  • We engage everyone, from the board to staff levels of the organization, in race equity work and ensure that individuals understand their roles in creating culture such that one’s race identity has no influence on how they fare within the organization.